

Supplemental Figure 1. BDCA1^{+} DCs have a modest but significant effect on efferocytosis. PBMCs were assay for phagocytosis in the presence or absence of BDCA1+ DCs. (A) Flow cytometry scheme (B) Quantification MFI pHrodo.



Supplemental Fig. 2. Differentially expressed genes in SCARF1^{Lo} and SCARF1^{Hi} cells. (A) PBMCs (2x10^6) were incubated with apoptotic cells (2x10^6) for 4 hours. Cells were stained for flow cytometry and sorted into RNA lysis buffer. Shown is a representative experiment out of n=4. (B) Heatmap of Top 150 Nanostring genes. Live BDCA1$^+$ DCs were sorted into SCARF1 negative (SCARF1^{Lo}) or SCARF1 positive (SCARF1^{Hi}) cells. mRNA was extracted, and the genetic profiling was measured using a Nanostring immunology panel. Gene expression as log 2 after normalization using Morpheus software. Shown is a representative heatmap of a single Nanostring assay (n=4). U, unstimulated. P values by Student's *t*-test.



Supplemental Figure 3. IgG depletion restores efferocytosis. Ablation of IgG increases apoptotic cell uptake in SLE patients. (A) Diagram of experimental design. (B-D) IgG and autoantibodies to SCARF1 depleted from serum. We depleted 20% serum in RPMI, healthy or SLE, using 100μL of Protein A/G agarose beads columns. IgG depletion was confirmed by Coomasie stain (B) and Western Blot (C). SCARF1 binding was analyzed by Dot Blot. Recombinant protein was transfer to nitrocellulose membrane, and full or depleted serum was used as a primary antibody. Human IgG was used as secondary antibody. Representative blot (n=13 SLE and n=8 Healthy). Anti-SCARF1 was use a control. (E-H) Ig-Depletion restores efferocytosis in SLE patient serum. PBMCs ($1x10^6$/mL) were incubated with full serum, or Ig-depleted serum for 20–24 hours. FBS was used as serum control. (E-F) Flow cytometry schematic. Cells were incubated for 3 hours with pHrodo red-labeled apoptotic cells ($2x10^6$/mL). Cells were stained and analyzed by flow cytometry. (G-H) Representative histograms of pHrodo expression to measure phagocytosis. Blue line, full serum; Red line, Ig-depleted serum. Total number of $CD11c^+BDCA1^+SCARF1^+$ measure by flow cytometry in the presence of full serum or Ig-depleted serum. Data represent the mean (±SEM) of 2 independent experiments n=13 SLE and n=8 Healthy, by Two-way ANOVA.

Supplemental Table 1. **Prevalence of SCARF1 in clinical makers during SLE disease**				
	Overall	**Scarf1 ab positive**	**Scarf1 ab negative**	**p value**
	146	30	116	
Female, n (%)	131 (90)	30 (100)	101 (87)	0.04
Age, mean (SD)	45 (14.5)	42 (16.5)	45 (13.9)	0.34
SLE features, n (%)				
Rashes/ alopecia	87 (60)	17 (57)	70 (60)	0.41
Photosensitivity	32 (22)	5 (17)	27 (23)	0.45
Arthritis	107 (73)	20 (67)	87 (75)	0.36
Hematologic	51 (35)	13 (43)	38 (33)	0.28
Serositis	40 (27)	9 (30)	31 (27)	0.72
Oral ulcers	22 (15)	4 (13)	18 (16)	0.77
Nephritis	46 (32)	10 (33)	36 (31)	0.81
Antiphospholipid antibody syndrome	23 (16)	4 (13)	19 (16)	0.68
Cardiovascular	9 (6)	2 (7)	7 (6)	0.90
Neurologic	16 (11)	2 (7)	14 (12)	0.40
Raynaud's	39 (27)	6 (20)	33 (28)	0.35
Vasculitis	6 (4)	0	6 (5)	0.35
Serology (n, %)				
ANA	138 (95)*	29 (97)	109 (94)	0.56
dsDNA	91 (62)	25 (83)	66 (57)	<0.01
Smith	57 (39)	19 (63)	38 (33)	<0.01
RNP	68 (47)	20 (67)	48 (41)	0.01
SSA (Ro)	46 (32)	11 (37)	35 (30)	0.49
SSB (La)	24 (16)	5 (17)	19 (16)	0.97
Antiphospholipid antibodies	37 (25)	4 (13)	33 (28)	0.09
Hypocomplementemia	65 (45)	15 (50)	50 (43)	0.50
Current SLE activity, n (%)				
Active	45 (31)	9 (30)	36 (31)	0.91
Remission or Low disease activity	78 (53)	17 (57)	61 (53)	0.69
Unknown	23 (16)	4 (13)	19 (16)	0.68
Current SLE Medications, n (%)				
Glucocorticoids	45 (31)	12 (40)	33 (28)	0.22
Hydroxychloroquine	83 (57)	20 (67)	63 (54)	0.22
Oral immunosuppressant	50 (34)	7 (23)	37 (32)	0.36
Biologic immunosuppressant	13 (9)	3 (11)	10 (9)	0.81
missing value in 7				